Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549664 · ClinicalTrials.gov registry record
Exercise in Genetic Cardiovascular Conditions
A clinical trial of Hypertrophic Cardiomyopathy and Long QT Syndrome, sponsored by Yale University.
- Completed
- Registry status
- 4,299
- Enrollment target
- 20
- Study locations
NCT02549664: Completed study of Hypertrophic Cardiomyopathy and Long QT Syndrome, sponsored by Yale University.
NCT02549664 is a study of Hypertrophic Cardiomyopathy and Long QT Syndrome that has completed, run by Yale University. The registered enrollment target is 4,299 participants, above the 921-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (367% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02549664, a study of Hypertrophic Cardiomyopathy and Long QT Syndrome, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 4,299 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS). Ancillary study Aim: To understand how the coronavirus epidemic is impacting psychological health and quality of life in the LIVE population
Primary Outcome
Collect information for death, resuscitated arrest, syncope, appropriate ICD shock , during exercise or at other times, through records from the provider and patient interviews
Conditions Studied
Study Locations (20)
California
- University of California Irvine - Orange
- University of California, San Diego (Rady's Children's Hospital) - San Diego
- Stanford - Stanford
Massachusetts
- Tufts - Boston
- Boston Children's - Boston
- Brigham & Women's - Boston
Arizona
- University of Arizona - Tucson
Connecticut
- Yale University - New Haven
District of Columbia
- Children's National - Washington D.C.
Florida
- Miami Children's (Nicklaus Children's Hospital) - Miami
Illinois
- Lurie Children's - Chicago
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,299 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2022-11-14 |
What the finished NCT02549664 record still lists
NCT02549664 is an observational study that tracks outcomes without assigning an intervention. Its 4,299 participants enrollment target places it among the larger protocols in the corpus, above the 921-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (367% higher).
The record links to 2 conditions, with Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT02549664 names 20 study sites across 16 states, led by California, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT02549664 about?
NCT02549664 is a clinical study titled "Exercise in Genetic Cardiovascular Conditions". The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS). Ancillary study Aim: To understand how the coronavirus epidemic is impacting psychological health and quality of life in the LIVE population
What is the current status of trial NCT02549664?
This trial is currently completed. The enrollment target is 4,299 participants. The study started on 2015-05-01. Estimated completion is 2022-11-14.
What conditions does trial NCT02549664 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy, Long QT Syndrome.
Who is sponsoring clinical trial NCT02549664?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02549664 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02549664's enrollment target sits among peer trials
4,299 2nd of 10 the highest of 10 other Hypertrophic Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertrophic Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
VIZ ACCESS HCM - Multi-Site Registry
RECRUITING
-
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
RECRUITING · NA
-
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
RECRUITING · Phase 1
-
Mavacamten Pregnancy Surveillance Program
RECRUITING
-
Pediatric Cardiomyopathy Mutation Analysis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI